Skip to main
ATAI

ATAI Stock Forecast & Price Target

ATAI Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 0%
Hold 57%
Sell 0%
Strong Sell 0%

Bulls say

AtaiBeckley is on track to revolutionize mental health treatments with its innovative pipeline, including BPL-003, VLS-01, and EMP-01, which are in Phase 2 development for TRD and social anxiety disorder. Recent acquisition by Eli Lilly, a major pharmaceutical company, solidifies the company's promising outlook, with a cash upfront price of $6.75 per share, plus a contingent value right of up to $2.50 per share tied to development and regulatory milestones. These milestones add potential additional value of up to $1 billion, making the total deal worth approximately $3.8 billion, a significant premium to AtaiBeckley's 30-day volume-weighted average trading price.

Bears say

AtaiBeckley is heavily reliant on BPL-003, a mebufotenin benzoate nasal spray for treatment-resistant depression (TRD), which is currently in Phase 3 clinical development and expected to drive over $2 billion in sales by 2035 with a 60% probability of success. However, there is potential competition from Spravato, and AtaiBeckley's transformation to a fully owned asset model will be crucial in driving shareholder value. Their financial success will heavily depend on the success and market adoption of BPL-003.

ATAI has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 0% recommend Buy, 57% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atai Life Sciences BV (ATAI) Forecast

Analysts have given ATAI a Buy based on their latest research and market trends.

According to 7 analysts, ATAI has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atai Life Sciences BV (ATAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.